SOURCE: BioServe

February 26, 2008 09:00 ET

BioServe Expands Global Customer Base

New Business in Second Half of 2007 Is a Testament to the Value of Human Bio-Samples for Validating Diagnostic Markers and Drug Discovery

BELTSVILLE, MD--(Marketwire - February 26, 2008) - BioServe today announced that in the second half of 2007 it has signed 211 agreements with leading biotechnology and pharmaceutical customers including Novartis, Sanofi -- Aventis, Broad Institute, Genentech, National Cancer Institute, Baylor University and Health Canada. In addition, BioServe hit an annualized growth rate of over 300 percent from fiscal year 2006.

Since acquiring Genomics Collaborative in May 2007, BioServe has acquired 76 new customers, providing them with access to its 600,000-sample Global Repository® of well-phenotyped human DNA, serum and tissue, as well as its gene expression and biomarker validation services.

"Our performance leaves little doubt that pharmaceutical and diagnostic development has embraced the power of clinical bio-specimens for more efficient identification of new drug and diagnostic targets," said Dr. Kevin Krenitsky, Chief Executive Officer of BioServe. "To help our customers fully realize the benefits of genomics in their research and discovery efforts, BioServe offers access to the broadest spectrum of human samples -- tissue, serum and DNA from globally-relevant populations -- and the expertise to process those samples to identify and validate new markers."

BioServe's services platform extends from molecular research products and services, such as DNA and RNA extraction and purification reagents, DNA sequencing, oligonucleotide synthesis and genotyping to ready-made large epidemiologically sound case-control studies of diabetes, obesity and cancers including breast, prostate, lung and colorectal.

Krenitsky added, "In 2008, we are off to a strong start that will be marked by the introduction of several novel bio-sample and processing products to increase the utility and application of human bio-samples for a larger portion of the research and development community. We will continue to expand our Global Repository, and we anticipate the worldwide commercialization of BioServe's first molecular diagnostic test for colorectal cancer developed with Phenonenome Discoveries, Inc."

About BioServe

BioServe is a leader in the processing, development, and validation of diagnostic tests for the practice of personalized, predictive and preventive medicine. Leading pharma, biotech and diagnostic firms collaborate with BioServe to identify and validate markers that cause disease while correlating clinical and molecular data to develop new diagnostic tests promoting wellness around the world. BioServe offers the Global Repository®, a growing library of over 600,000 human DNA, tissue and serum samples linked to detailed clinical and demographic data from 140,000 consented and anonymized patients from four continents. Leveraging BioServe's robust genomic analytical services, technology, Global Repository and CLIA-certified laboratory, collaborators gain a complete, highly efficient platform for processing diagnostic test results and identifying genomic markers for powerful new assays. BioServe has headquarters in Beltsville, MD and Hyderabad, India. For more information please visit www.bioserve.com or call 301-470-3362.

Contact Information

  • Contacts:
    Kevin Krenitsky
    Chief Executive Officer
    BioServe
    301-470-3362
    Email Contact

    Constantine Theodoropulos
    Boston Communications
    617-292-7319
    Email Contact